UNSPSC 51432600: Antihypertensive piperazines

Antihypertensive drugs made from organic compounds composed of a six-membered ring containing two nitrogen atoms at opposite positions (hexa-hydro-pyrazine(s)).

UNSPSC 51432600 Antihypertensive piperazines, a Class code, encompasses pharmaceutical procurement by state and local health agencies for emergency medical services, public health programs, and multistate cooperative purchasing vehicles. State and local governments buy specific branded and generic formulations of antihypertensive medications—including labetalol, diltiazem, and related piperazine-based compounds—for use in emergency response, hospital formularies, and pharmacy benefit programs serving employees and Medicaid populations. Issuing bodies include municipal fire and rescue departments, state health and human services agencies, and multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions. Recent opportunities show fire rescue services procurement alongside state-level strategic initiatives to establish direct-to-manufacturer relationships and competitive generic pharmaceutical supply contracts.

Recent activity concentrates in Florida and Minnesota, with Texas exploring direct-to-manufacturer models. The City of Tampa's Purchasing Department issued IFB 26-P-00188 on April 24, 2026 (due April 8, 2026) for Advanced Life Support Medications including labetalol HCl 100mg vials and diltiazem 25mg vials for Tampa Fire Rescue, with an estimated contract value of $40,000 and a one-year initial term plus renewal options; the bid included a 5 percent Small Local Business Enterprise discount and required nine-month minimum expiration dates with 10-day delivery terms. The Minnesota Department of Administration's Office of State Procurement issued RFP S1070000015802 on January 20, 2026 (due March 26, 2026) through the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) for generic multi-source pharmaceuticals and OTC products distributed across Minnesota and Oregon, with pricing weighted at 75 percent, vendor payments of a 3 percent administrative fee, and a two-year contract term effective July 1, 2026. Texas Health and Human Services Commission issued RFI HHS0017013 in late March 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer program, representing preliminary market research before formal procurement.